ASX All ords biotech stock explodes 120% on regulatory green light

The company has hit a milestone with its cancer diagnostics test.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • This biotech company is charging 120% higher so far today 
  •  Investors appear to be excited by news related to a screening test for colorectal cancer
  • The All Ords is 0.42% in the red today 

The All Ordinaries Index (ASX: XAO) is down 0.42% in lunchtime trading, but this ASX All Ords biotech stock is bucking the trend.

The Rhythm Biosciences Ltd (ASX: RHY) share price is rocketing 120% higher today to 77 cents.

Let's take a look at what this ASX ALL Ords share reported to the market.

What's going on?

Rhythm shares appear to be storming higher today amid a major regulatory milestone.

The cancer diagnostics company has received UK Conformity Assessment (UKCA) Mark certification for ColoSTAT, a blood test that screens for colorectal cancer. The test is aimed at global mass market screening.

This will enable Rhythm to commercialise, market, and sell ColoSTAT in the United Kingdom, reaching a market of up to 24 million people aged between 45 and 74.

Rhythm is optimistic it will make further inroads with its UK market entry during the 2023 calendar year.

Commenting on the news, Rhythm chief commercial officer Elena Deak said:

The achievement of this regulatory milestone continues to validate our commercial pathway into global markets, with the UK alone representing an addressable population of approximately 24 million people.

Importantly, over time we expect the market size to continue expanding, as various bodies encourage earlier age screening.

The UKCA Mark is a new post-Brexit UK product marking required for products being commercialised in Great Britain.

Share price snapshot

Rhythm shares have declined nearly 40% in the last year. However, with today's gains, they have soared 43% in the last month.

Created with Highcharts 11.4.3Rhythm Biosciences PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

This ASX All Ords share has a market cap of about $255.2 million based on the latest share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »